Department of Veterinary and Biomedical Sciences and Center for Molecular Toxicology and Carcinogenesis, Penn State University, 325 Life Sciences Building, University Park, PA 16802, USA.
PPAR Res. 2013;2013:121956. doi: 10.1155/2013/121956. Epub 2013 May 2.
PPARβ/δ is a ligand-activated transcription factor that regulates various cellular functions via induction of target genes directly or in concert with its associated transcriptional repressor, BCL-6. Matrix remodeling proteinases are frequently over-expressed in pancreatic cancer and are involved with metastasis. The present study tested the hypothesis that PPARβ/δ is expressed in human pancreatic cancer cells and that its activation could regulate MMP-9, decreasing cancer cells ability to transverse the basement membrane. In human pancreatic cancer tissue there was significantly higher expression of MMP-9 and PPARβ/δ, and lower levels of BCL-6 mRNA. PPARβ/δ activation reduced the TNF α -induced expression of various genes implicated in metastasis and reduced the invasion through a basement membrane in cell culture models. Through the use of short hairpin RNA inhibitors of PPARβ/δ, BCL-6, and MMP-9, it was evident that PPARβ/δ was responsible for the ligand-dependent effects whereas BCL-6 dissociation upon GW501516 treatment was ultimately responsible for decreasing MMP-9 expression and hence invasion activity. These results suggest that PPARβ/δ plays a role in regulating pancreatic cancer cell invasion through regulation of genes via ligand-dependent release of BCL-6 and that activation of the receptor may provide an alternative therapeutic method for controlling migration and metastasis.
过氧化物酶体增殖物激活受体β/δ(PPARβ/δ)是一种配体激活的转录因子,通过直接诱导靶基因或与相关转录抑制因子 BCL-6 协同作用来调节各种细胞功能。基质重塑蛋白酶在胰腺癌中经常过度表达,并与转移有关。本研究检验了以下假设:PPARβ/δ 在人胰腺癌细胞中表达,其激活可以调节 MMP-9,降低癌细胞穿过基底膜的能力。在人胰腺癌组织中,MMP-9 和 PPARβ/δ 的表达明显升高,而 BCL-6 mRNA 的水平较低。PPARβ/δ 的激活降低了 TNFα 诱导的各种与转移相关基因的表达,并降低了细胞培养模型中穿过基底膜的侵袭。通过使用 PPARβ/δ、BCL-6 和 MMP-9 的短发夹 RNA 抑制剂,显然 PPARβ/δ 负责配体依赖性效应,而 GW501516 处理后 BCL-6 的解离最终负责降低 MMP-9 的表达和侵袭活性。这些结果表明,PPARβ/δ 通过配体依赖性释放 BCL-6 调节基因来调节胰腺癌细胞的侵袭,并且受体的激活可能为控制迁移和转移提供一种替代的治疗方法。